Episodic Vs. Continuous Readiness: Which Operating Model Is Carrying Your Biotech Forward?

By Lola Furlong

Navigating the transition toward Investigational New Drug (IND) filings requires biotech organizations to evaluate whether their quality operating model is simply audit-ready or truly scale-ready. Being audit-ready allows a company to periodically assemble evidence to pass inspections, whereas being scale-ready establishes an infrastructure that maintains continuous compliance as clinical complexity, vendor partnerships, and documentation volumes grow.

Relying on episodic readiness forces senior talent to bridge system gaps through manual coordination, creating hidden execution risks during critical inflection points like Phase I trials or contract manufacturing expansions. Transitioning to a continuous readiness model integrates evidence generation, vendor oversight, and risk management directly into daily operations. Evaluate your current quality infrastructure to transition from reactive audit preparation to continuous compliance.